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Introduction: Antibiotic resistance is a growing concern in health care. Methicillin-resistant 
Staphylococcus aureus (MRSA), forming biofilms, is a common cause of resistant orthopedic 
implant infections. Gentamicin is a crucial antibiotic preventing orthopedic infections. 
Silica–gentamicin (SiO
2
-G) delivery systems have attracted significant interest in preventing 
the formation of biofilms. However, compelling scientific evidence addressing their efficacy 
against planktonic MRSA and MRSA biofilms is still lacking, and their safety has not extensively 
been studied.
Materials and methods: In this work, we have investigated the effects of SiO
2
-G nanohybrids 
against planktonic MRSA as well as MRSA and Escherichia coli biofilms and then evaluated 




-G nanohybrids inhibited the growth and killed planktonic MRSA at a minimum 
concentration of 500 µg/mL. SiO
2
-G nanohybrids entirely eradicated E. coli cells in biofilms at 
a minimum concentration of 250 µg/mL and utterly deformed their ultrastructure through the 
deterioration of bacterial shapes and wrinkling of their cell walls. Zebrafish embryos exposed 
to SiO
2
-G nanohybrids (500 and 1,000 µg/mL) showed a nonsignificant increase in mortality 
rates, 13.4±9.4 and 15%±7.1%, respectively, mainly detected 24 hours post fertilization (hpf). 
Frequencies of malformations were significantly different from the control group only 24 hpf 
at the higher exposure concentration.
Conclusion: Collectively, this work provides the first comprehensive in vivo assessment of 
SiO
2
-G nanohybrids as a biocompatible drug delivery system and describes the efficacy of SiO
2
-G 
nanohybrids in combating planktonic MRSA cells and eradicating E. coli biofilms.
Keywords: SiO
2
, gentamicin, MRSA, antibacterial and antibiofilm effects, nanotoxicity, 
zebrafish
Introduction
Antibiotic resistance is a current hot topic and a significant threat to health care. The 
antibiotic-resistant bacterium, methicillin-resistant Staphylococcus aureus (MRSA), is 
at the heart of most clinical cases of notorious orthopedic surgery infections.1 S. aureus 
is also a principal etiological agent of device-related infections and can adhere to the 
implanted orthopedic devices and then colonize their surfaces forming biofilms.2–4 
Biofilms are aggregates of bacterial cells enclosed in a diffuse polymeric matrix.5–8 
Biofilm matrix is resistant to the host immune response and antibacterial agents, 
which has led to the challenge of treating biofilms,2,7,9 to the surgical removal of the 
implanted device to eliminate the infection,4,6 and to remarkable morbidity and mortality 
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rates of the patients within hospital settings.2 Biofilms also 
form complex pedestal-like structures, water channels, and 
pores,8 making them physiologically and morphologically 
different from their planktonic counterparts.10–12 The differ-
ent resistance mechanisms of biofilms to antibiotics have 
been grouped in a previous review7 as follows: 1) the slow 
penetration of antibiotics into the biofilm matrix; 2) the altera-
tion of the chemical microenvironment within the biofilms, 
antagonizing the action of antibiotics; and 3) the formation 
of a highly protected spore-like states by the subbacterial 
populations of biofilms. Concrete data speaking for the sole 
responsibility of any of such resistance mechanisms are still 
lacking.6,13 Furthermore, old biofilms are highly resistant to 
antibiotics and antibacterial agents.11,14 It has previously been 
observed that tobramycin (5 µg/mL) kills 97% of the young 
(2 days) biofilms of Pseudomonas aeruginosa after 4 hours 
treatment. However, even a higher tobramycin concentration 
(50 µg/mL) kills only 50% of the old (7 days) biofilms.15 Toté 
et al16 have found that different biocides reduce the number 
of viable S. aureus and P. aeruginosa cells in biofilms but 
the matrices of biofilms are not affected. Allan et al17 have 
shown that killing Escherichia coli cells with commercial 
disinfectants, in most cases, requires at least double the 
concentration of disinfectant when the cells were in biofilms 
compared with that needed for planktonic cells. Choi et al18 
have reported a fourfold increase in the minimum bactericidal 
concentration (MBC) of silver nanoparticles (NPs) required 
for E. coli cells in biofilms compared with that needed for 
planktonic cells. Such tenacity of the formed biofilms is the 
leading cause to remove the infected orthopedic implants 
and to treat the infections before implanting new devices.19 
Consequently, therapeutic modalities that could target the 
antibiotics, preventing the formation of biofilms, would be 
an effective way to control them.5
Generally speaking, silica (SiO
2
)-based formulations 
could be utilized for the targeted drug delivery and for 
squelching the intricate multidrug resistance.20,21 More spe-
cifically, SiO
2
 materials could be utilized as local antibiotic 
delivery systems in orthopedic implants targeting effective 
antibiotic concentrations in bone tissue and avoiding the 
drawbacks of systemic antibiotic administrations, like toxicity 
or limited tissue exposure.3 Aminoglycosides (i.e., gentamicin 
and kanamycin), glycopeptide antibiotics (i.e., vancomycin), 
and quinolones (i.e., ciprofloxacin) have broadly been utilized 
in orthopedic surgery, preventing or treating associated infec-
tions.1 There are a large number of published studies on load-
ing antibiotics onto SiO
2
 materials for the prolonged localized 
drug delivery applications, as described for gentamicin22–27 
and vancomycin.28,29 It has been demonstrated that kanamy-
cin-resistant E. coli is susceptible to kanamycin-conjugated 
SiO
2
 NPs, though it is resistant to pristine kanamycin, 
because of the modified antibacterial mechanism of action 
of kanamycin conjugated to SiO
2
 NPs.30 However, none of 
those above studies has investigated the antibiofilm effects 
of antibiotic-loaded SiO
2
 NPs against S. aureus biofilms to 
ascertain their efficacy in orthopedic applications.
In our previous research,27 we have demonstrated better 
antibacterial effects of silica–gentamicin (SiO
2
-G) nanohy-
brids against Bacillus subtilis than Pseudomonas fluorescens 
or E. coli. However, further research is needed on bacterial 
strains most commonly involved in orthopedic applications, 
like S. aureus and their biofilms, to reveal the practical 
potential of the nanohybrids. Therefore, this study determines 
the antibacterial and antibiofilm effects of SiO
2
-G nano-
hybrids against MRSA and MRSA biofilms, respectively, 
for promising orthopedic applications. Bacterial motility 
constitutes a critical virulence factor in bacterial coloniza-
tion by initiating the contact of bacterial cells with surfaces.8 
A recent study31 has paid attention to the role of bacterial 
morphology in adhesion to immobilized liquid layers under 
dynamic conditions, advocating the more efficient adhesion 
of E. coli cells in comparison with that of S. aureus and 
P. aeruginosa, under dynamic conditions, to the flagella of 
E. coli. Furthermore, the most predominant clinical bacteria 
involved in orthopedic implant infections belong to the 
Staphylococcus genus followed by Enterobacteriaceae 
genus. Infections by Enterobacteriaceae are encountered 
with implants being surgically incised near to prenieums.32 
The well-known genetics and the wealth of other knowledge 
collected on E. coli support its use as an exemplary model for 
studying the formation of biofilms.8 Therefore, the present 
study aims to enhance the understanding of the antibiofilm 
effects of the SiO
2
-G nanohybrids by also exploring such 
effects on E. coli biofilms.
Despite the importance of SiO
2
-G delivery systems, the 
safety and risks associated with their use have not been widely 
documented. Combining in vitro and in vivo toxicological 
data on nanomaterials, concerning their physicochemical 
properties, can help in predicting safety when designing 
nanomaterials.33 However, studies on the subject have been 
conflicting and mostly restricted to SiO
2
 NPs. Some studies 
have shown that SiO
2
 NPs decrease the viability of different 
cell lines such as that of human brain microvessel endothelial 
cells,34 human umbilical vein endothelial cells,35 and human 
lung epithelial BEAS-2B cells (only at $500 µg/mL of 
positively charged SiO
2
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It has also been shown that SiO
2
 NPs significantly decrease 
the differentiation capacity of human mesenchymal stem 
cells.37 By contrast, a detailed examination of the toxicity of 
SiO
2
 NPs in 19 different cell lines has demonstrated minimal 
toxicity in all the cell lines tested.38 We have recently defined 
the in vitro effects of SiO
2
-G nanohybrids (719±128 nm) 
on the osteogenesis of human osteoblast-like SaOS-2 cells, 
detecting a lower expression of the alkaline phosphatase 
but enhanced mineralization of the extracellular matrix at 
250 µg/mL.39 To better control the safety of such delivery 
systems, it is of paramount importance to couple the in vitro 
toxicological effects of these engineered nanomaterials with 
in vivo studies in more complex animal models.40 Zebrafish 
embryos are an outstanding animal model for screening 
chemical toxicity and nanotoxicity in vivo due to several 
advantages: 1) the genome similarity between zebrafish 
and humans makes the screening relevant to human health; 
2) pores (diameter of 0.5–0.7 µm) in zebrafish chorions 
allow for the permeation of xenobiotics; 3) the transparency 
of embryos permits microscopic imaging; 4) the survival of 
embryos in the absence of functional cardiovascular system 
facilitates accurate cardiotoxicity studies.41 Another crucial 
aspect making zebrafish embryos an excellent animal model is 
that they have, similar to human embryos, protruded yolk sacs 
that supply proteins, lipids, and micronutrients, facilitating 
the growth of embryos.42 In the context of bone research, the 
key regulators of bone formation are also similar in zebrafish 
and mammals, providing a possibility to correlate the find-
ings in zebrafish to mammalian bone metabolism.43–45 Taking 
advantage of their transparency, chondrocytes and osteoblasts 
can be conveniently monitored over time.43 Duan et al46 have 
demonstrated that SiO
2
 NPs (diameter of 62 nm; 0.1 and 
0.2 mg/mL) significantly decrease the hatching rates and 
increase the mortalities of zebrafish embryos. These previous 
results, however, differ from those of Sharif et al,47 who did 
not detect toxic effects for the injected mesoporous SiO
2
 NPs 
(diameter of 200 nm; 10 mg/mL) in zebrafish embryos, defin-
ing such SiO
2
 NPs as a suitable delivery system. Therefore, 
to clarify the nebulous and conflicting toxicity data of SiO
2
 
NPs among in vitro and in vivo studies, we have also studied, 
in the present work, the in vivo toxic effects of SiO
2
-G nano-
hybrids in zebrafish embryos. To the best of our knowledge, 
this is the first study to explore the toxic effects of SiO
2
-G 
nanohybrids in this experimental model. Drawing upon the 
present two avenues of research on SiO
2
-G nanohybrids for 
safe orthopedic applications, the present study first attempts 
to demonstrate the antibacterial effects of SiO
2
-G nanohybrids 
against planktonic MRSA and their antibiofilm effects against 
MRSA and E. coli biofilms and second, assesses their in vivo 
toxic effects in zebrafish embryos.
Materials and methods
Materials
The gentamicin sulfate, tetraethyl orthosilicate ($99.0%), 
and ammonium hydroxide (28%–30%) were obtained from 
Sigma-Aldrich Co. (St Louis, MO, USA). The MRSA strain 
(S. aureus subsp. aureus ATCC® 43300™; KWIK-STIK™) 
was purchased from Microbiologics® (St Cloud, MN, USA) 
and the E. coli strain (ATCC 11775™) was obtained from 
VTT Culture Collection. The Calgary biofilm device (CBD), 
commercially available as the MBEC™ (minimum biofilm 
eradication concentration) biofilm inoculator with a 96-well 
base and hydroxyapatite-coated pegs (19131) was purchased 
from Innovotech Inc. (Edmonton, AB, Canada).




-G nanohybrids were prepared according to the 
procedure used by Corrêa et al.48 Five hundred milligrams of 
gentamicin sulfate was dissolved in 10 mL of tetraethyl ortho-
silicate and 20 mL of ammonium hydroxide was then added to 
the solution, which was subjected to stirring for 20 minutes at 
ambient temperature until precipitation. Following precipita-
tion, the material was dried overnight at ambient temperature 
and then ground. The pristine SiO
2
 NPs were prepared using 
the same procedure without adding gentamicin sulfate.
characterization of siO2-g nanohybrids 
and pristine siO2 NPs
The prepared materials were then characterized by scan-
ning electron microscope (SEM), zeta potential analyses, 
transmission electron microscope (TEM), and attenuated 
total reflectance-Fourier transform infrared (ATR-FTIR) 
spectroscopy. The SEM analyses were performed to analyze 
the surface morphology of the materials prepared, using 
Zeiss Sigma VP SEM with an acceleration voltage of 1.5 kV 
and a secondary electron detector. Before SEM analyses, 
the samples were sputter coated with a platinum (Pt) target 
for 1.5 minutes (yielding a Pt layer of ~8.6 nm thickness), 
using an Emitech K100X sputter coater. The zeta potential 
of the materials suspended in deionized water was measured 
using the SZ-100 nanopartica Zetasizer (Horiba Scientific, 
Kyoto, Japan) in triplicate. The TEM studies were performed 
using a Hitachi TEM (H-7650B, Hitachi, Tokyo, Japan) 
and a JEOL TEM (JEM-2800, JEOL, Tokyo, Japan) micro-
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respectively. The size of the pristine SiO
2
 NPs was analyzed 
on the obtained TEM images, whereas the size of the SiO
2
-G 
nanohybrids was analyzed on the obtained SEM and TEM 
images, trying to capture less aggregated particles. The size 
analysis was executed using Fiji ImageJ software. ATR-FTIR 
was recorded using a Nicolet 380 FT-IR (Thermo Electron 
Corporation, White Bear Lake, MN, USA) spectrometer, with 
a resolution of 2 cm−1 and a scan range of 4,000–500 cm−1. 
The spectra were the means of 64 scans.
Antibacterial and antibiofilm tests
The MRSA and E. coli strains were cultivated aerobically on 
Luria-Bertani agar overnight at 35°C. The disinfection of the 
powder form SiO
2
-G nanohybrids and pristine gentamicin 
was conducted by UV irradiation (GS Gene Linker® UV 
Chamber, Bio-Rad Laboratories Inc., Hercules, CA, USA) 
for 90 seconds before the antibacterial and antibiofilm tests. 
Following disinfection, SiO
2
-G nanohybrids and gentamicin 
were suspended and dissolved in sterile deionized water 
(1 mg/mL), respectively. The suspended SiO
2
-G nanohybrids 
were then sonicated for 30 minutes (VWR® Ultrasonic Bath, 
USC 200 T, power 60 W, ultrasonic frequency 45 kHz), 
obtaining homogeneous solutions, before the tests. The 
CBD was used to determine the susceptibilities of the bio-
films to the materials tested. A universal neutralizer (1.0 g 
l-histidine, 1.0 g l-cysteine, and 2.0 g reduced glutathione in 
20 mL double distilled water) was prepared, sterilized using 
a 0.2 µm cellulose acetate membranes, and stored at −20°C. 
Five milliliters of the prepared universal neutralizer was 
then added to 200 mL Mueller–Hinton broth (MHB) to be 
further added into the wells of the recovery plates used in 
the biofilm susceptibility tests.
agar diffusion assay
The susceptibility tests were conducted on the planktonic 
MRSA cells following the guidelines described by the 
Clinical and Laboratory Standards Institute (CLSI).49 Briefly, 
aliquots of 100 µL of MRSA suspension (~1–2×108 colony-
forming units [CFUs]/mL) were spread on Mueller–Hinton 
agar plates. Aliquots of 50 µL of SiO
2
-G nanohybrids 
(1 mg/mL) and pristine gentamicin (1 mg/mL and 25 µg/mL) 
were then dispensed into the 5 mm-diameter wells of the 
plates. Following overnight incubation of the plates at 35°C, 
the diameters of inhibition zones (IZs, mm) were measured. 
Three separate experiments were performed on different 
days. The results were interpreted following the tables of 
the CLSI document.50
Minimum inhibitory concentration (MIc) 
and MBc
The MIC of the SiO
2
-G nanohybrids and pristine gentamicin 
against planktonic MRSA cells was determined using the 
broth microdilution method following the guidelines of 
the CLSI.51 Twofold serial dilutions (from 1 mg/mL to 
1 µg/mL) of the SiO
2
-G nanohybrids and pristine gentamicin 
were prepared in MHB in the wells of a microtiter plate. 
Within 15 minutes of the inoculum preparation (density 
adjusted to the same turbidity as McFarland standard 0.5), 
the inoculum was diluted and then inoculated into the wells 
(10 µL per well), achieving a final bacterial concentration 
of 5×105 CFU/mL and representing 10% of the volume per 
well. Uninoculated MHB was used as a negative control, 
and an MRSA suspension was used as a positive control for 
growth. The MICs were visually recorded after overnight 
incubation at 35°C in sealed plastic bags to avoid drying. 
To detect bacterial eradication by the materials tested, the 
MBC was detected following the guidelines of the CLSI,52 
using the microdilution endpoints. Aliquots of 10 µL of the 
wells showing the MICs (clear) were spot plated on Mueller–
Hinton agar plates. The number of the cultured colonies was 
used to determine the bactericidal endpoints based on the 
final inoculum (5×105 CFU/mL) and the rejection values 
of the tables of the CLSI.52 Two separate experiments were 
performed on different days.
Biofilm susceptibilities using CBD
Aliquots (150 µL) of MRSA and E. coli dilutions (final 
bacterial concentrations of ~105–106 CFU/mL) were added 
into the wells of the 96-well microtiter plates of the MBEC 
biofilm inoculator, excluding the sterility control wells (only 
MHB). The peg lids were then inserted into the plates, and 
the devices were incubated, under dynamic conditions, in a 
shaking incubator (110 rpm) for 24 hours at 35°C. Specified 
pegs were removed from the lids, using sterilized pliers, and 
put into the wells of a 96-well microtiter plate containing 
MHB (200 µL). The biofilms were detached by shaking 
for 30 minutes (160 rpm). The biofilm viabilities were then 
detected by serially diluting and spot plating (20 µL).
Another 96-well microtiter plate was used as the 
antibacterial challenge plate. The working solutions of the 
SiO
2
-G nanohybrids and pristine gentamicin were used 
as 1×, 2×, and 4× of their MICs against planktonic cells 
of MRSA and E. coli. The concentrations of the SiO
2
-G 
nanohybrids tested were 500, 1,000, and 2,000 µg/mL and 
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and E. coli, respectively. The concentrations of the pristine 
gentamicin tested were 125, 250, and 500 µg/mL and 7.8, 
15.6, and 31.3 µg/mL against the biofilms of MRSA and E. 
coli, respectively. The contact time with the materials was 
set as 24 hours in a shaking incubator. A rinse plate was also 
prepared by adding 200 µL of sterile saline (0.9%) per well. 
The peg lids containing the biofilms were immersed in saline 
before and after the antibacterial challenge for 2 minutes, 
rinsing the dispersed cells from the biofilms.
After the challenge, the MBEC peg lid was transferred 
to the recovery plate containing 200 µL of the universal 
neutralizer per well. The pegs were neutralized in the 
recovery plate for 30 minutes to equilibrate the antibacterial 
materials tested and the biofilms were detached by shaking 
(160 rpm) for 30 minutes. Aliquots of 20 µL were serially 
diluted and spot plated to detect the viable counts per peg 
using Equation 1. Then, aliquots of 20 µL of fresh MHB 
medium were added to the wells of the recovery plates, which 
were then sealed and incubated for another 24 hours at 35°C 
with shaking (110 rpm). The MBEC was visually detected 
after the incubation as the minimal concentration of the mate-
rials tested eradicating the MRSA biofilms. Two separate 
experiments were performed on different days. Each separate 























= ( ) + 
 
(1)
X, CFU counted on spot plate; B, volume plated; D, dilu-
tion factor.
SEM examination was also executed on the biofilms formed 
onto the CBD pegs following the standard protocol described 
by Harrison et al53 with modifications. Briefly, after the anti-
bacterial challenge and rinsing, the desired pegs were broken 
from the lid by sterilized pliers. The broken pegs were rinsed 
for 15 minutes in 200 µL sterile saline (0.9%) in the wells of 
a 96-well microtiter plate, removing the dispersed planktonic 
cells from the pegs. The pegs were then placed in sterile 
Eppendorf Tubes (2 mL) and fixed by adding 300 µL of 5% 
glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4) and kept 
at 4°C for 24 hours. After this fixation, the pegs were washed 
first with cacodylate buffer (0.1 M, 300 µL, 15 minutes) and 
second with sterile distilled water (300 µL, 15 minutes). The 
pegs were postfixed with 1% cacodylate-buffered osmium 
tetroxide (pH 7.4) at room temperature for 1 hour. The pegs 
were then dehydrated using increased ethanol concentrations 
(50%, 70%, 96%, and 100%) and finally acetone (100%), and 
critical point dried at 1,200 bar pressure at 40°C using liquid 
CO
2
. The samples were then mounted on aluminum stubs and 
sputter coated with a Pt target for 4 minutes (yielding a Pt layer 
of ~22.8 nm thickness). All the samples were then analyzed 
using the Zeiss Sigma VP SEM with an acceleration voltage 
of 1.5 kV and a secondary electron detector.
Zebrafish strain and setup of exposure 
to siO2-g nanohybrids
The Tübingen strain of zebrafish (Danio rerio) was used in 
this study. The ethical approval was obtained from the Animal 
Care and Use Committee of Tsinghua University. The embryos 
were collected after natural spawning of adults maintained at 
the light:dark photoperiods of 14:10 hours and incubated in 
Holtfreter’s medium at 28°C±2°C. The embryonic develop-
mental stages were defined as previously reported by Kimmel 
et al.54 The collected embryos were placed in Petri dishes and 
examined by a stereomicroscope, removing dead embryos. The 
sterilization of the powder form SiO
2
-G nanohybrids was con-
ducted by 60Co irradiation at a dose of 10 kGy before the in vivo 
experiments. At 4 hours post fertilization (hpf), the embryos 
were divided into three groups (30 embryos per group), and each 
group was placed into a separate well of a 6-well culture plate. 
The first group was exposed to pure Holtfreter’s medium (3 mL, 
with no test materials) and used as a negative control. The sec-
ond and third groups were exposed to the SiO
2
-G nanohybrids in 
Holtfreter’s medium at concentrations of 500 and 1,000 µg/mL, 
respectively. The Holtfreter’s medium (pure and containing the 
materials tested) was changed every 24 hours until the end of 
the experiment at 5 days post fertilization (dpf).
Mortality, hatching, and cardiac rates
Zebrafish embryos/larvae were evaluated for the toxic effects 
of the SiO
2
-G nanohybrids. The mortality rates were recorded 
every 24 hours, starting at 24 hpf, as the percentage of dead 
embryos/larvae of all embryos in the group. The hatching rates 
were recorded as the percentage of hatched embryos at 72 hpf 
of all the living embryos in the group. The cardiac rates were 
detected by counting the beating of ventricles per minute under 
a stereomicroscope (Nikon SMZ 1500, Nikon Corporation, 
Tokyo, Japan) after being mounted in 3% methylcellulose 
on the top of a depressed glass slide, starting at 72 hpf. Two 
separate experiments were performed on different days.
Malformations of embryos/larvae
The malformations of zebrafish embryos/larvae exposed to 
the SiO
2
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24 hours, starting at 24 hpf. The malformed embryos/larvae 
were mounted in 3% methylcellulose on the top of a depressed 
glass slide, anesthetized by 0.1% tricaine, and captured using 
a stereomicroscope with Nikon Digital Sight camera (Ds-Ri1, 
Nikon Corporation). The phenotypic endpoints used to 
evaluate the malformations were pericardial sacs, yolk, body 
growth, spine, and tail. For estimating the severity of mal-
formations and toxicity at exposure to the materials tested, 
the embryos/larvae were scored from 0 to 4 based on the 
conceptual scaling criteria proposed by Heiden et al55 with 
a slight modification. The scaling criteria were as follows: 
0, absence of malformations; 1, single malformation; 2, two 
malformations; 3, severe three or more malformations; and 4, 
lethality. The scoring spectrum (1, 2, and 3; representing 
various degrees of malformations) values were determined 
at each time point and then accumulated, forging an average 
semiquantitative toxicity profile for each exposure group 
of the SiO
2
-G nanohybrids (see Supplementary materials). 
Score 0 represents the normally developed embryos/larvae, 
and score 4 represents the percentage of mortality. The 
percentage of malformed embryos/larvae was recorded every 
24 hours of the living embryos in the group. An advantage 
of using the percentage of malformations is to identify the 
common malformations induced by SiO
2
-G nanohybrids 
in comparison with the control group. To achieve this, the 
percentage of malformation was also determined by dividing 
the number of embryos/larvae developed a specific type of 
malformation in the group by the total number of malformed 
embryos/larvae in all the groups. Two separate experiments 
were performed on different days.
statistical analysis
The data obtained were analyzed using Student’s t-tests 
(two-tailed, unequal variance) to determine the P-values 
using Microsoft Excel (Office Professional Plus 2016, 
Impressa Systems, Santa Rosa, CA, USA). The results were 
expressed as mean ± standard deviation. Values of P,0.05 
were considered statistically significant.
Results and discussion
characterization of siO2-g nanohybrids 
and pristine siO2 NPs
The results obtained from the SEM analyses of the prepared 
pristine SiO
2
 NPs and SiO
2
-G nanohybrids are compared 
in Figure 1. The pristine SiO
2
 NPs (Figure 1A and C) 
demonstrate smooth spherical morphology that differs 
from the granular rough aggregated network of the SiO
2
-G 
nanohybrids (Figure 1B and D). This surface roughness of 
the SiO
2
-G nanohybrids validates the loading of gentamicin, 
providing means for the initial fast gentamicin release 
demonstrated in our previous study.27 It also matches with 
previous data that link the rough surfaces with the enhanced 
antibiotic release,56,57 especially at the initial stages of bone 
surgery to prevent osteomyelitis.58 The difference between 





-G nanohybrids is highlighted in Figure 1E 
and was detected as −61.6±0.9 mV and −9±1.5 mV, respec-
tively. This decrease in the negative charge of the SiO
2
-G 
nanohybrids, compared with that of the pristine SiO
2
 NPs, 
is apparently attributed to the loaded gentamicin, suggesting 
an electrostatic interaction between the positively charged 
antibiotic and the negatively charged pristine SiO
2
 NPs. 
The present results are in accordance with those of Mebert 
et al59 who found that the most massive amount of positively 
charged gentamicin was incorporated into the most nega-
tively charged SiO
2
 NPs by an adsorption process governed 
by electrostatic interactions.
The TEM images (Figure 2) envisage the remarkably 





-G nanohybrids. It can be seen that the pristine 
SiO
2
 NPs (Figure 2A and C) are somewhat monodisperse 
with a mean diameter (Figure 2E) of 293±21 nm and size 
distribution of 254–325 nm (Figure S1A). In contrast, the 
SiO
2
-G nanohybrids (Figure 2B and D) tend to unite and form 
aggregated networks with a striking increase in the mean 
diameter (Figure 2E) to 879±264 nm and a considerable vari-
ation in the size distribution of 453–1,248 nm (Figure S1B). 
The decrease in the zeta potential after the gentamicin loading 
also contributes to the reduction in the repulsive forces of 
the nanohybrids, facilitating such network aggregation. This 
increase in size is consistent with our earlier observations,27,39 
suggesting the loading of gentamicin onto the surface and 
in the SiO
2
 matrix. To some extent, this outcome supports 
that of Alvarez et al60 who detected an increase in the size 
of SiO
2
 from 441±5 nm to 511±38 nm after gentamicin 
loading with a slight decrease in the negative surface charge 
from −47±5 mV to −43±7 mV, respectively. The observed 
correlation between the present dramatic increase in the size 
of the nanohybrids after gentamicin loading and the dramatic 
decrease in their negative charge might be explained in the 
following way: the more efficient decrease in the negative 
charge facilitates more efficient uniting of the nanohybrids 
and a more prominent increase in their size. Interestingly, 
additional thin layers are also observed on the surface of the 
SiO
2
-G nanohybrids (Figure 2D), representing the surface-
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Figure 1 seM images of the materials.
Notes: (A, C) smooth spherical pristine siO2 NPs and (B, D) granular rough aggregated network of siO2-G nanohybrids at the magnifications of 10,000× (A, B) and 20,000× 
(C, D). (E) The zeta potential of the pristine siO2 NPs and siO2-g nanohybrids in deionized water. The error bars represent the standard errors of the means.
Abbreviations: seM, scanning electron microscope; siO2 NPs, silica nanoparticles; siO2-g, silica–gentamicin.
reported by the appearance of the bands of gentamicin (see 
Supplementary materials) in the ATR-FTIR spectrum of the 
nanohybrids (Figure S2).
antibacterial effects of siO2-g 
nanohybrids against planktonic Mrsa 
cells
To compare the antibacterial effects of the SiO
2
-G nanohy-
brids and pristine gentamicin, IZs were first measured in agar 
diffusion assays after 24 hours. It is somewhat surprising 
that no IZ was observed by pristine gentamicin (25 µg/mL). 
On the contrary, the SiO
2
-G nanohybrids (1 mg/mL), releasing 
the same concentration of gentamicin (25.05 µg/mL) after 
24 hours as determined in our previous study,27 elicited IZs 
of 10.7±0.6 mm (Figure 3A and B). To find a reasonable 
inhibitory concentration of the SiO
2
-G nanohybrids against 
MRSA, the MIC and MBC were second identified against 
planktonic MRSA cells. According to the data in Figures 3C 
and S3, the MICs and MBCs were 500 and 125 µg/mL for 
the SiO
2
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Figure 2 TeM images of the materials.
Notes: (A, C) Pristine siO2 NPs and (B, D) siO2-G nanohybrids. The surface-loaded gentamicin is marked red with dashed shapes in panel D. Magnifications of 8,000× 
(A), 60,000× (B), and 10,000× (C, D). (E) The size of the pristine siO2 and siO2-g nanohybrids analyzed on the obtained TeM, and seM and TeM images, respectively. 
The error bars represent the standard errors of the means.
Abbreviations: seM, scanning electron microscope; siO2 NPs, silica nanoparticles; siO2-g, silica–gentamicin; TeM, transmission electron microscope.
However, the SiO
2
-G nanohybrids release only ~12.5 µg 
gentamicin/mL at their MIC,27 indicating that the SiO
2
-G 
nanohybrids are aptly more effective than pristine gentamicin 
(MIC, 125 µg/mL) to inhibit the tenacious MRSA cells. 
The most explicit finding to emerge from the present tests 
is that the SiO
2
-G nanohybrids can overcome the resistance 
of MRSA against pristine gentamicin, by even releasing less 
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(µg/mL) 500 250 125 62.5 31.3 15.6 7.8 3.9 2 1
Figure 3 antibacterial effects of the materials tested.
Notes: (A) agar diffusion assay of the siO2-g nanohybrids (1 mg/ml) and pristine gentamicin (1 mg/ml) against planktonic Mrsa cells, highlighting the IZs with dashed red 
and violet circles, respectively. The inset shows the lack of IZ by pristine gentamicin (25 µg/ml). (B) The diameters of IZs. The error bars represent the standard errors 
of the means. (C) MIcs of the siO2-g nanohybrids (500 µg/ml) and pristine gentamicin (g, 125 µg/ml) against planktonic Mrsa cells, highlighting the clear wells in siO2-g 
nanohybrids and gentamicin assays with red and violet rectangles, respectively. +c, positive control, an Mrsa suspension showing a button of bacterial growth. −c, negative 
control, uninoculated MhB.
Abbreviations: g, gentamicin; IZs, inhibition zones; MhB, Mueller–hinton broth; MIcs, minimum inhibitory concentrations; Mrsa, methicillin-resistant Staphylococcus 
aureus; siO2-g, silica–gentamicin.
performed with biofilms,57 which showed that the reduction 
of S. aureus biofilm growth did not necessarily correlate 
with the amount of gentamicin released from different bone 
cement. Some bone cement showed a more significant reduc-
tion of S. aureus biofilms, by even releasing less gentamicin 
compared with other bone cement in the same study.
Antibiofilm effects of SiO2-g nanohybrids 
and pristine gentamicin
To determine the susceptibilities of the preformed MRSA and 
E. coli biofilms, under dynamic conditions, on the pegs of 
the CBD to the SiO
2
-G nanohybrids and pristine gentamicin 
tested, the viable counts of bacterial cells in biofilms were 
first compared after neutralization and plating as shown in 
Figure 4 and Table S1. Log
10
 numbers of the viable counts 
of MRSA cells in the positive control biofilms are presented 
in Figure 4A. The viable counts of MRSA cells in the bio-
films were not reduced after treatment with the different 
concentrations (1×, 2×, and 4× of the MICs recorded for the 
planktonic MRSA cells) of SiO
2
-G nanohybrids and pristine 
gentamicin (Figure 4A). These nonreduced viable counts 
highlight the problem of the stubborn resistance of MRSA 
cells in biofilms. Interestingly, as shown in Figure 4B, there 
were significant differences between log
10
 numbers of the 
viable counts of E. coli cells in the positive control bio-
films and the biofilms treated with the SiO
2
-G nanohybrids 
(P=0.002 for the three concentrations tested) and pristine 
gentamicin (P=0.002 for the highest concentration tested). 
SiO
2
-G nanohybrids had entirely eradicated the E. coli bio-
films with an MBEC recorded as 250 µg/mL. The correlation 
between the presently recorded MBEC of the SiO
2
-G nano-
hybrids against E. coli cells in biofilms and the same previ-
ously recorded MIC (250 µg/mL) against planktonic E. coli 
cells27 is of interest. Counting CFUs in the biofilms is one 
of the principal ways to delineate the efficient diffusion of 
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Figure 4 Antibiofilm effects of the materials tested.
Notes: Mean of log10 numbers of the viable cells (cFU/peg) in Mrsa (A) and E. coli (B) biofilms counted by spot plating of the dispersed cells from the pegs after 
neutralization. The error bars represent the standard errors of the means. The data shown are representative of two separate experiments. *P,0.05 and **P,0.01 indicate 
significant differences compared with the control using Student’s t-test (two-tailed, unequal variance).
Abbreviations: c, control; cFU, colony-forming units; E. coli, Escherichia coli; g, gentamicin; Mrsa, methicillin-resistant Staphylococcus aureus; siO2-g, silica–gentamicin.
diffusion is demonstrated by recording similar MICs for the 
cells in the biofilms and the planktonic form.9 This similar 
MBEC and MIC underpin the SiO
2
-G nanohybrids as a 
promising delivery system releasing effective gentamicin 
concentrations that diffuse through and entirely eradicate the 
E. coli biofilms. Pristine gentamicin also eradicated E. coli 
biofilms with an MBEC recorded as 7.8 µg/mL (Figure 4B), 
which places E. coli cells in biofilms within the intermediate 
range of susceptibility according to the MIC standards of the 
CLSI for planktonic cells.50
To further investigate the susceptibility of the preformed 
biofilms to the materials tested, the pegs of the CBD were 
visualized by SEM (Figures 5, S4 and S5). The architecture 
of the MRSA biofilms (Figure 5A and B) appeared to be 
unaffected by the treatment with the SiO
2
-G nanohybrids 
and pristine gentamicin. In contrast, there were interesting 
differences between the architecture of the untreated E. coli 
biofilms and the biofilms treated with the SiO
2
-G nanohy-
brids and pristine gentamicin (Figure 5C and D). SiO
2
-G 
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Figure 5 SEM images of the susceptibility of preformed biofilms to the materials tested.
Notes: (A, B) Mrsa and (C, D) E. coli biofilms formed on the pegs of the CBD in the absence (control) or presence of the SiO2-g nanohybrids or g, respectively, taken at 
the magnifications of 5,000× (A, C) and 10,000× (B, D). Red circles demonstrate the intact ultrastructure of the MRSA biofilms treated with the SiO2-g nanohybrids. Violet 
ellipses demonstrate scattered E. coli cells with a slightly deformed ultrastructure in biofilms treated with G.
Abbreviations: CBD, Calgary biofilm device; E. coli, Escherichia coli; g, pristine gentamicin; Mrsa, methicillin-resistant Staphylococcus aureus; seM, scanning electron 
microscope; siO2-g, silica–gentamicin.
deformation of the E. coli biofilms in the form of an utter 
deterioration of cell shapes and apt damage and wrinkling 
of their cell walls. E. coli biofilms treated with pristine gen-
tamicin demonstrated a scattered distribution of few cells 
with a slightly deformed ultrastructure.
Due to the tedious techniques needed for cultivating 
and quantifying biofilm growth and subsequently adopting 
antimicrobial screening programs, it is of paramount impor-
tance to develop rapid screening methods for evaluating the 
antimicrobial susceptibilities of bacteria following biofilm 
formation.14 Consequently, we have utilized the CBD as a 
reliable and rapid method to detect the biofilm susceptibilities 
to the SiO
2
-G nanohybrids. The CBD can aptly reproduce 
biofilm formation and mimic in vivo biofilms, and it facilitates 
the characterization of the formed biofilms by microscopic 
techniques.9 A robust relationship between ultrasound waves 
and the destroyed ultrastructure of biofilms, increasing the 
bactericidal effect of antibiotics, has been reported in the 
literature.61 This relationship was exemplified in the work of 
Rediske et al,62 which illustrated that high-intensity ultrasonic 
pulses eradicate E. coli biofilms on subcutaneously implanted 
disks in rabbits receiving systemic gentamicin treatment with 
no adverse effects on the skin integrity. Furthermore, there is 
little agreement on the sonication time required to detach the 
biofilms, ranging from as short as 60 seconds in the modified 
Robbins device57,63 to 5 minutes in both 96-well polystyrene 
microtiter plates64 and the CBD,65 or also increasing in the 
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also found that the continuous flow of medium in the modified 
Robbins device facilitates the detachment of fragments of the 
formed biofilms (24 hours) on the gentamicin-loaded bone 
cement. Consequently, high rates of shaking (160 rpm) for a 
long time (30 minutes), instead of sonication, were adopted in 
the present study to detach the biofilms. This shaking played 
a crucial role in excluding errors originating from the dam-
age of bacterial cells in biofilms after ultrasonication, thus 
facilitating a more accurate quantification of viable cells in 
the biofilms. It also offered a way to exclude the inconsistency 
reported in the literature for the sonication time required to 
detach the biofilms.
The combination of the present findings suggests the fol-
lowing: first, the SiO
2
-G nanohybrids can combat the resis-
tance of planktonic MRSA cells against pristine gentamicin. 
This combating of resistance facilitates the use of such deliv-
ery systems to prevent the formation of biofilms composed 
of stubborn MRSA strains. Second, SiO
2
-G nanohybrids 
can entirely eradicate the preformed E. coli biofilms but 
not MRSA biofilms. The deterioration of the shape and the 
reduction of the size of E. coli cells in biofilms treated with 
the SiO
2
-G nanohybrids are more pronounced and complete, 
as observed by SEM than seen with pristine gentamicin. 
Therefore, the SiO
2
-G nanohybrids can combat the virulence 
of E. coli cells in biofilms, which is mainly attributed to their 
flagella, allowing for surface colonization.8 The SiO
2
-G nano-
hybrids thus possess superior antibiofilm effects compared 
with pristine gentamicin. A recent study67 has reported a 
change in the surface charge of liposomal gentamicin from 
−54.5 to 17.5 mV after association with lysozyme and specu-
lated the role of this surface charge in the antibiofilm effects 
of the lysozyme-associated liposomal gentamicin. The change 
in surface charge might facilitate an electrostatic attraction 
of the positively charged lysozyme-associated liposomal 
gentamicin to the negative charge of alginate in the biofilm 
matrix. This change in the surface charge resembles, to some 
extent, our results showing the decrease of the negative 
charge from −61.6±0.9 mV to −9±1.5 mV for the pristine 
SiO
2
 NPs and SiO
2
-G nanohybrids, respectively. In contrast, 
prior studies68,69 have noted an intense inhibition of diffusion 
of the positively charged pristine gentamicin (aminoglyco-
side) through biofilm layers after binding to the negatively 
charged alginate in the biofilm matrix. Consequently, one 
of the remarkable findings to emerge from the present study 
is that SiO
2
-G delivery systems preserve the full utilization of 
the gentamicin released to combat preformed E. coli cells in 
biofilms, instead of being entirely sequestered by the negative 
charge of the biofilm matrix. While seeking a reasonable 
explanation for the absence of antibiofilm effects of the 
nanohybrids against MRSA cells in biofilms, it is noteworthy 
that another study70 has shown enhanced antibiofilm effects of 
an NP-stabilized capsule with a core of cinnamaldehyde dis-
solved in peppermint oil. In that study, the enhanced effects 
against MRSA biofilms were attributed to the cationic nature 
of the capsule enabling more interactions with the biofilms 
and the acidic nature of the biofilms breaking the capsule and 
releasing more cinnamaldehyde. Consequently, the surface 
charge of the present SiO
2
-G delivery systems enabled the 
full utilization of gentamicin against E. coli cells in biofilms 
but was not cationic enough to allow the interaction of the 
nanohybrids with MRSA biofilms.
In vivo toxic effects of siO2-g 
nanohybrids in zebrafish embryos/larvae
To enable the use of SiO
2
-G nanohybrids as delivery systems 
in orthopedic applications, the possible toxicity of SiO
2
-G 
nanohybrids was assessed in vivo in the second avenue of 
the present research through evaluating a series of endpoints 
in zebrafish embryos/larvae. The exposure concentrations 
(500 and 1,000 µg/mL) represented multiples of the MIC of 
the planktonic MRSA cells (1× and 2×) and MBEC of E. coli 
biofilms (2× and 4×), respectively. The results obtained from 
the continuous monitoring of the mortality rates are presented 
in Figure 6A. The embryos exposed to the SiO
2
-G nanohybrids 
demonstrated higher mortality rates than the control group. 
However, this increase in the mortality rates was not significant 
(P.0.05) and was mainly detected at the embryonic devel-
opmental stage of 24 hpf, as 13.4%±9.4% and 15%±7.1% at 
the exposure to 500 and 1,000 µg/mL of SiO
2
-G nanohybrids, 
respectively, in comparison with the 3.3% mortality in the con-
trol group. The mortality rate slightly increased over time (120 
hpf) at the exposure to 500 µg/mL of the nanohybrids, reaching 
16.7%±9.4%. Despite this, the mortality rates recorded at the 
exposure to 1,000 µg/mL of the nanohybrids and the control 
group remained consistent 24 hpf and over the time (120 hpf), 
underpinning the absence of a time-dependent increase in the 
mortality rates. Concerning the hatching rates, all the embryos 
exposed to the SiO
2
-G nanohybrids (500 and 1,000 µg/mL) 
demonstrated normal 100% hatching rates after 72 hours, in 
the same way as the control group. A comparison of the con-
tinuous monitoring of the cardiac rates of the embryos/larvae 
exposed to the SiO
2
-G nanohybrids (500 and 1,000 µg/mL) 
and the control group are presented in Figure 6B and Table S2. 
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C SiO2-G (500 µg/mL) SiO2-G (1,000 µg/mL)
Figure 6 In vivo toxic effects of the materials tested.
Notes: (A) Mortality and (B) cardiac rates of zebrafish embryos/larvae exposed to the SiO2-g nanohybrids (500 and 1,000 µg/ml). The mortality rates demonstrated 
a nonsignificant increase mainly 24 hpf, after exposure to the nanohybrids at the concentrations of 500 and 1,000 µg/ml. embryos/larvae exposed to the nanohybrids 
demonstrated a slight tachycardia at the concentrations of 500 and 1,000 µg/ml. The error bars represent the standard errors of the means of two separate experiments, 
30 embryos in each group. all the P-values are .0.05 compared with the control group using student’s t-tests (two-tailed, unequal variance).
Abbreviations: c, control group; siO2-g, silica–gentamicin.
(P.0.05) in the cardiac rates (tachycardia) at the exposure to 
the SiO
2
-G nanohybrids at the two concentrations tested. This 
tachycardia indicates that the SiO
2
-G nanohybrids may lead 
to slight cardiac arrhythmias.
In Figure 7, images of the control group provide an 
overview of the normal developmental stages of zebrafish 
embryos/larvae. The exposure of embryos/larvae to the SiO
2
-G 
nanohybrids (500 and 1,000 µg/mL) ignites the scenery with 
a throng of sublethal malformations (Figure 7 and Figure S6), 
including pericardial edema; yolk sac edema (YSE) or yolk 
not depleted (YND); stunted growth (SG); spinal deformity 
(SD); and tail malformation (TM) or broken tail (BT). 
To address a semiquantitative toxicity profile for each expo-
sure group of the SiO
2
-G nanohybrids (500 and 1,000 µg/mL), 
the scoring spectrum (1, 2, and 3; defining various degrees of 
malformations) values were determined at each time point 
and then accumulated. The normally developed embryos/
larvae represent score 0. The dead embryos/larvae represent 
score 4 and were recognized in the mortality recordings. The 
scoring spectra and cumulative values are shown in Table S3 
and Figure S7. A closer inspection of the average cumulative 
scores and the exposure concentrations demonstrate that the 
lower exposure concentration (500 µg/mL) showed average 
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Figure 7 Malformations of zebrafish embryos/larvae.
Notes: Microscopic images (3X objective) of different developmental stages of zebrafish embryos/larvae 24 hpf (A), 48 hpf (B), 72 hpf (C), and 96 hpf (D). The control group 
presents the normal development of the embryos/larvae with no malformations (score: 0). The embryos treated with the siO2-g nanohybrids (500 and 1,000 µg/ml) show a 
range of malformations, such as Yse or YND, sD, sg, TM, and Pe. The severity of malformations is scored (1–4). The highest score, 4, is marked for the De.
Abbreviations: De, degenerated embryos; Pe, pericardial edema; sD, spinal deformity; sg, stunted growth; siO2-g, silica–gentamicin; TM, tail malformation; YND, yolk 
not depleted; Yse, yolk sac edema.
1, 2, and 3, respectively. In contrast, the higher exposure 
concentration (1,000 µg/mL) showed average cumulative 
scores of 28±9.6, 27.4±15.9, and 12±8.4 for scores 1, 2, 
and 3, respectively. These data suggest the preeminence of 
scores 3 and 1 as average cumulative toxicity profiles for 
the lower (500 µg/mL) and higher (1,000 µg/mL) exposure 
concentrations, respectively.
Frequencies of malformations induced by the exposure to 
both concentrations tested were generally similar (Figure 8). 
On the contrary, the frequency of malformations induced 
by the SiO
2
-G nanohybrids 24 hpf was noticeable when 
compared with the control group (4%±0.4% at the concentra-
tion of 1,000 µg/mL vs 0% for the control group). This differ-
ence reached a statistical significance (P=0.04) and reflected, 
to some extent, the recorded higher mortality rates induced 
by this concentration at the embryonic developmental stage 
of 24 hpf. The most common sublethal malformations 
(Figure S8) developed by zebrafish embryos/larvae exposed 
to the SiO
2
-G nanohybrids were YSE or YND (30.6%±27.5%) 
followed by TM or BT (29.2%±5.9%) for the lower exposure 
concentration (500 µg/mL). YSE or YND (34.1%±30.5%) 
followed by SD (23%±14.7%) were the most common mal-
formations recorded for the higher exposure concentration 
(1,000 µg/mL) of the SiO
2
-G nanohybrids. Taken together, 
the present results suggest that YSE or YND, TM or BT, 
and SD are the common malformations developed by the 
embryos/larvae at the exposure to the SiO
2
-G nanohybrids. 
However, the overall incidences of these common malforma-
tions (Figure S8) were not significantly different from those 
in the control group for either exposure concentrations.
The present study has, for the first time, addressed 
the crucial questions of the in vivo toxicity of the SiO
2
-G 
nanohybrids using zebrafish embryos, to enable their safe 
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Figure 8 Frequencies of malformations of zebrafish embryos/larvae.
Notes: siO2-g nanohybrids (500 and 1,000 µg/ml) induced frequencies of malformations at different developmental stages. The error bars represent the standard errors 
of the means of two separate experiments, using 30 embryos in each group. *P,0.05 is significant compared with the control group using Student’s t-test (two-tailed, 
unequal variance).
Abbreviations: siO2-g, silica–gentamicin; c, control group.
the importance of the size of NPs in the toxicity elicited 
in zebrafish embryos; for example, smaller Ag NPs have 
induced more in vivo toxicity.71–73 When considering the 
role of the size of NPs in the in vivo toxicity, the chorionic 
pores of the embryos should also merit attention. Lee et al74 
have shown the passive diffusion of Ag NPs (30–72 nm) 
through the chorionic pore canals (0.5–0.7 µm) of the 
embryos and the clogging of the pores by the aggregation 
of Ag NPs. As far as SiO
2
 toxicity is concerned, Duan et al46 
have reported a dose- and time-dependent increase in the 
mortality and hatching rates of zebrafish embryos treated 
by SiO
2
 NPs (62 nm). More specifically, the in vitro toxicity 
of SiO
2
-G nanohybrids (719±128 nm) has been identified 
in our earlier study,39 showing a significant time-dependent 
decrease in the viability of human osteoblast-like SaOS-2 
cells. Only 25%±1% of cells are viable after 5 days at the 
nanohybrid concentration of 250 µg/mL. This cell viability 
indicates severe cytotoxicity of the SiO
2
-G nanohybrids at the 
concentration of 250 µg/mL. The present results, in contrast, 
show a nonsignificant increase in the mortality rates (120 hpf) 
at both exposure concentrations of the SiO
2
-G nanohybrids 
(500 and 1,000 µg/mL) tested and the foremost increase in 
the mortality rates recorded 24 hpf, with almost no time-
dependent increase in the mortalities of the treated embryos/
larvae. Furthermore, all the embryos exposed to the SiO
2
-G 
nanohybrids (500 and 1,000 µg/mL) hatched normally 
(48 hpf) and only showed a slight nonsignificant increase in 
the cardiac rates. These contradictory findings between our 
previous in vitro studies39 and the present in vivo investiga-
tions obtained even using the same synthesis strategy of the 
SiO
2
-G nanohybrids are apparently attributed to the size of 
the SiO
2
-G nanohybrids (879±264 nm). The chorionic pore 
diameter hinders the full diffusion of the large-sized nano-
hybrids into the embryonic tissues. The higher mortality 
rates recorded in the time frame around 24 hpf in the present 
study resemble the findings of Lee et al,75 who defined the 
embryonic late segmentation stage (21–23 hpf), showing the 
highest mortalities as the most sensitive stage of zebrafish 
embryos to the toxicities induced by Ag NPs (13.1±2.5 nm). 
The embryonic hatching stage (48–50 hpf) was defined as 
the most resistant stage to the toxicities of Ag NPs in the 
same study.
Regarding the scoring spectra and the frequencies of 
malformations, it is somewhat surprising that the aver-
age cumulative scoring toxicity profile was higher for the 
lower exposure concentration, although the frequency of 
malformations (Figure 8) at different developmental stages 
was not significantly different from the control group. In 
contrast, the higher exposure concentration had a lower aver-
age cumulative scoring toxicity profile and a significantly 
different incidence of malformations (Figure 8), from the 
control group, recorded at 24 hpf. This significant differ-
ent incidence of malformations can also correlate with the 
slightly higher mortality rates recorded for the higher expo-
sure concentration only 24 hpf and can specify a possible 
dose-dependent sublethal toxicity (malformations) for the 
nanohybrids at the exposure of the embryos to the higher 
exposure concentration, only 24 hpf. This dose-dependent 
sublethal toxicity seems to happen only at 24 hpf because of 
the sensitivity of the embryos at this stage. Furthermore, the 
small chorionic pore diameter hindered the full diffusion of 
the large-sized SiO
2
-G nanohybrids; consequently, only the 
sublethal toxicity reached a significant level at this stage, 
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significant levels even at the higher exposure concentration. 
Similar to the mortality rates (showing almost no time-
dependent increase), there was no increase in the cumulative 
scoring profile of all the time points at the higher exposure 
concentration. Thus far, the present results provide further 
support for the hypothesis that the late segmentation stage is 
the most sensitive stage to the toxicities elicited by SiO
2
-G 
nanohybrids. The crucial role of the size of the SiO
2
-G nano-
hybrids is also emphasized at the embryonic developmental 
stage of 24 hpf through the nonsignificant increase in the 
mortality rates recorded in the exposed embryos at this stage 
and in the significant malformations recorded only at 24 hpf 
at the higher exposure concentration.
Proceeding now to the common malformations devel-
oped by the embryos/larvae at the exposure to the SiO
2
-G 
nanohybrids, YSE or YND, TM or BT, and SD were the 
common malformations recorded. The present results match 
those observed in an earlier study,46 recording YSE and TMs 
as common malformations induced by SiO
2
 NPs. The pres-
ently demonstrated deficiency in yolk utilization can explain 
the SG shown in this study as it infers that the embryos 
were not using all the yolk nutrients required for growth.42,71 
Overall, while the present study shows neither significant 
mortalities nor significant common malformations induced 
by the exposure of the embryos to the SiO
2
-G nanohybrids, 
it does point towards the pivotal role of the large size of the 
nanohybrids. This large size possibly causes less diffusion 
of the nanohybrids into the embryonic tissue, governed by 
the chorionic pore diameter, and consequently, decreases 
the elicited in vivo toxicity of the embryos exposed to the 
SiO
2
-G nanohybrids. Relating the mild or nonsignificant 
effects caused by the SiO
2
-G nanohybrids in vivo in the pres-
ent study to our previously recorded significant cytotoxicity 
of the SiO
2
-G nanohybrids towards human osteoblast-like 
SaOS-2 cells39 adds more complexity to the safety issues in 
using the SiO
2
-G nanohybrids as an antibiotic delivery system 
in orthopedic applications. These discrepancies between the 
in vitro and in vivo levels of toxicity of the same nanoma-
terials are consistent with data obtained in earlier studies. 
These earlier data, however, have shown more toxic effects 
in zebrafish embryos than in mammalian cells using Ag NPs 
(size of 95.68 nm dispersed in water)76 or metal-organic 
frameworks (diameter of 170 nm).77
In a nutshell, the present study has identified different 
approaches to combating the resistance of planktonic MRSA 
cells to gentamicin as well as for the complete eradication of 
preformed E. coli biofilms. These results highlight the possi-
bility to use the SiO
2
-G nanohybrids as an antibiotic delivery 
system in orthopedic applications, preventing the formation 
of biofilms and eradicating the preformed biofilms of MRSA 
and E. coli, respectively. Even though the mortality rates of the 
zebrafish embryos exposed to the SiO
2
-G nanohybrids remained 
statistically nonsignificant, this addresses the two sides of the 
same coin: 1) the possible biocompatibility of such delivery 
systems in orthopedic applications, and 2) the complexities and 
uncertainties associated with the safety issues of such delivery 
systems. These uncertainties result from the difficulty to inter-
pret the discrepancies between the results of in vivo and in vitro 
studies in the present and our previous work,39 respectively.
Conclusion
This work is the first empirical investigation on SiO
2
-G nano-
hybrids (879±264 nm) using both in vitro assays (antibacte-
rial and antibiofilm effects) and in vivo toxicity assessments 
in zebrafish embryos. The main in vitro findings of this work 
are as follows: 1) The SiO
2
-G nanohybrids are more effec-
tive than pristine gentamicin against planktonic MRSA and 
E. coli biofilms. 2) The SiO
2
-G nanohybrids can destroy the 
tenacity of planktonic MRSA cells with a minimum inhibi-
tory and bactericidal concentration of 500 µg/mL. 3) The 
SiO
2
-G nanohybrids can entirely eradicate E. coli biofilms 
at a MBEC of 250 µg/mL. 4) The treatment of E. coli bio-
films with SiO
2
-G nanohybrids causes an utter ultrastructural 
deformation of E. coli cells, showing deformed cell shapes 
and wrinkled cell walls, as demonstrated by SEM. The main 
in vivo findings of this work are as follows: 1) 24 hpf is the 
most sensitive embryonic developmental stage to the toxicity 
of SiO
2
-G nanohybrids. 2) Even though only a nonsignificant 
increase in mortalities is detected in the exposed embryos 
24 hpf, malformations with significantly different frequency 
from the control group are also detected 24 hpf for the higher 
exposure concentration. 3) The large size of SiO
2
-G nano-
hybrids apparently plays a pivotal role in the nonsignificant 
occurrence of mortalities recorded in zebrafish embryos. 
4) Nondepleted yolk and SG types of malformations are the 
most common ones developed by zebrafish embryos/larvae, 
indicating the nonusage of the required nutrients in the yolk 
after exposure to the SiO
2
-G nanohybrids. Therefore, this 
work provides robust evidence for the use of the SiO
2
-G 
nanohybrids as biocompatible antibiotic delivery systems 
combating recalcitrant planktonic MRSA cells and prevent-
ing and eradicating MRSA and E. coli biofilms. However, 
more studies are needed to elucidate the in vivo toxic effects 
of smaller sized SiO
2
-G nanohybrids to conclusively demon-
strate the possibility of safely using such delivery systems. 
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action of the SiO
2
-G nanohybrids are also needed to decipher 
the basis for the better antibacterial and antibiofilm effects 
of the nanohybrids than pristine gentamicin.
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